Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
12 December, 2018 08:00 IST
Sun Pharma announces USFDA acceptance of NDA for OTX-101
Source: IRIS | 27 Dec, 2017, 10.08AM
Comments  |  Post Comment

Sun Pharmaceutical Industries announces that the US FDA has accepted a New Drug Application (NDA), filed by its wholly owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in a clear, preservative-free aqueous solution. OTX-101 is now under review for approval by the US FDA, marking an important developmental milestone for Sun Pharma's dry eye candidate.

Dilip Shanghvi, Managing Director, Sun Pharma, (Q,N,C,F)* said, ''Dry Eye disease is a complex, chronic condition that affects patient quality of life, often significantly. OTX-101, a novel formulation of cyclosporine, will allow us to participate in the rapidly growing underserved and dynamic Dry Eye market. When approved, it will be a milestone for millions of Dry Eye patients across the globe that are yet to find relief for their condition.''

Post the US FDA approval, OTX-101 will be commercialized in the US by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma's wholly owned subsidiary, based in Princeton, New Jersey. Sun Ophthalmics, founded in 2015, currently markets BromSite® (bromfenac ophthalmic solution) 0.075% to eye care practitioners across US.

Abhay Gandhi, CEO, North America Business, Sun Pharma, said, ''We are excited about the acceptance of this filing by the US FDA. In January 2017, we had announced positive topline results of confirmatory Phase-3 clinical trial for OTX-101, demonstrating both efficacy and faster onset of action in a trial environment. The 12 week trial saw 744 dry eye patients being treated either with OTX-101, or its vehicle. Compared to the vehicle, OTX-101 showed statistically significant improvement in the primary end point in the trial. The demonstration of efficacy of OTX-101 was earlier than other drugs approved for dry eye in the same class1. We hope to bring OTX-101 to patients in the United States as soon as possible, and look forward to working closely with the US FDA over the coming months.''

Shares of the company gained Rs 16.55, or 3.06%, to trade at Rs 557.00. The total volume of shares traded was 250,450 at the BSE (9.59 a.m., Wednesday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:26
Wipro Digital to expand Asia Pacific design capabilities in Australia - 11-Dec-2018 09:24
Lupin receives tentative USFDA approval for Apixaban tablets - 11-Dec-2018 09:20
Lupin receives EIR from USFDA for Indore facility - 10-Dec-2018 16:10
HCL Tech to acquire select IBM Software products for USD 1.8 bn - 07-Dec-2018 10:08
Wipro, Alfresco expand pact to offer digital transformation capabilities - 07-Dec-2018 09:59
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer